Programmed death axis 1 (PD-1) inhibitors have ushered in a new error of cancer immunotherapeutics for advanced smoking-associated non–small cell lung cancer. Their role in treating EGFR-mutant and ALK-rearranged lung cancer has yet to be determined. Clin Cancer Res; 22(18); 1–3. ©2016 AACR.
See related article by Gainor et al., p. 4585
- Received June 24, 2016.
- Accepted July 3, 2016.
- ©2016 American Association for Cancer Research.